Clinical Trials Logo

Filter by:
NCT ID: NCT04401969 Completed - Mycetoma Clinical Trials

Tissue Microenvironment Signatures of the Mycetoma Granuloma

Start date: March 7, 2019
Phase:
Study type: Observational

Mycetoma is the most neglected of the neglected tropical diseases. It is caused by certain fungi or bacteria. It is endemic in many tropical and subtropical regions and Sudan seems to be the mycetoma homeland. This chronic subcutaneous destructive and disabling inflammatory disease has many serious medical and socio-economic impacts on patients, community and health authorities. This work may suggest new therapeutic options for mycetoma that target the inflammatory pathogenic pathway and hence help in designing universal treatment options for mycetoma patients. Two overlapping aims were investigated in this project to advance our overall goals: 1. Profiling the immune/inflammatory signatures in the tissue microenvironment of fungus-induced mycetoma lesions 2. Profiling the immune/inflammatory signatures in the tissue microenvironment of bacteria-induced mycetoma lesions.

NCT ID: NCT03969134 Completed - Clinical trials for Leishmaniasis, Cutaneous

A Study to Assess the Safety, Efficacy and Immunogenicity of Leishmania Vaccine ChAd63-KH in PKDL

Start date: April 6, 2020
Phase: Phase 2
Study type: Interventional

This trial is designed to assess the therapeutic efficacy and safety of CHAd63-KH, a new candidate Leishmania vaccine, in patients with persistent PKDL. 100 participants will be randomly assigned (50 participants in each arm) to receive placebo or ChAd63-KH 7.5 x10(10)vp. Doses will be administered at a single time point.

NCT ID: NCT03138031 Completed - Clinical trials for Hepatocellular Carcinoma Non-resectable

Percutaneous Ethanol Alcohol Injection for the Large and Unresectable Hepatocellular Carcinoma

Start date: May 1, 2017
Phase: N/A
Study type: Interventional

Assessment of the long-term outcome of percutaneous ethanol alcohol injection (PEI) for the large and unresectable hepatocellular carcinoma: single center non-randomized trial.

NCT ID: NCT03129646 Completed - Clinical trials for Visceral Leishmaniasis

Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa

Start date: January 24, 2018
Phase: Phase 3
Study type: Interventional

This is an open label, Phase III, randomized, controlled, parallel arm multicentre non-inferiority clinical trial to compare the efficacy and safety of two combination regimens of Miltefosine and Paromomycin with the standard SSG-PM for the treatment of primary adult and children VL patients in Eastern Africa.

NCT ID: NCT02894008 Completed - Clinical trials for Leishmaniasis, Cutaneous

A Study of a New Leishmania Vaccine Candidate ChAd63-KH

Leish2a
Start date: November 2016
Phase: Phase 2
Study type: Interventional

This is a study to assess the safety of a new candidate Leishmania vaccine ChAd63-KH in patients with persistent post kala azar dermal leishmaniasis (PKDL). This is a Phase II trial in patients with PKDL, to assess the safety and compare the humoral and cellular immune responses generated by the candidate vaccine in patients, and observe any clinical changes in the disease over a 42 day period following vaccination. Study design: Eight adult volunteers will receive 1x10(10)vp and the subsequent eight volunteers will receive 7.5 x10(10)vp. Adolescents will be vaccinated with either 1x10(10)vp or 7.5 x10(10)vp, to be determined by evaluation of all available data after DSMB & CTSC review.

NCT ID: NCT02832544 Completed - Clinical trials for Rheumatic Heart Disease

INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Non-Inferiority

INVICTUS-VKA
Start date: August 22, 2016
Phase: Phase 3
Study type: Interventional

This program is a comprehensive evaluation of rheumatic valvular heart disease (RVHD), Atrial fibrillation (AF)/flutter and stroke. A prospective, randomized, parallel group, open-label clinical trial of rivaroxaban versus standard vitamin K antagonists (VKA) therapy to evaluate non-inferiority of rivaroxaban to VKA, with testing for superiority if non-inferiority is satisfied.

NCT ID: NCT02592408 Completed - Malaria Clinical Trials

A Study to Assess Current Standard Malaria Treatment Guidelines in the Republic of the Sudan

MalTreSu
Start date: November 2015
Phase: Phase 4
Study type: Interventional

This is a randomized controlled trial to assess the efficacy and safety of the national malaria treatment guidelines, asses the efficacy and safety of artesunate and sulphadoxine - pyrimethamine (AS+SP) for treatment in uncomplicated P. falciparum and P. vivax malaria and the hematologic effect of 14 days routine primaquine based radical cure in patients suffering from a P. vivax or mixed infection.

NCT ID: NCT02467257 Completed - Sickle Cell Anemia Clinical Trials

Gum Arabic as Fetal Hemoglobin Agent in Sickle Cell Anemia

Start date: April 2014
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine whether Gum Arabic is effective as fetal hemoglobin inducing agent for sickle cell anemia patients.

NCT ID: NCT02417337 Completed - Pain Clinical Trials

Efficacy of Different Drugs to Control Post Root Canal Treatment Pain

Start date: August 2012
Phase: Phase 2
Study type: Interventional

Root canal therapy will ideally eliminate post-endodontic pain but occasionally analgesics are needed to diminish the pain [1]. Development of pain after completion of root canal treatment may undermine patients' confidence in the procedure and the clinician [2]. Non-steroidal anti-inflammatory drugs are one of the most frequently taken analgesic medications for dental pain. Their popularity attributed to their efficacy in relieving pain and fever and low side effect profile at therapeutic doses [3]. Mono-therapy analgesic has a low effect on dental pain. Improvement was performance by combining analgesics with different mechanisms of action without raising any adverse effects [4], was effective in controlling moderate to severe pain. The combination of a non-steroidal anti-inflammatory drug (NSAID) and paracetamol has shown additive analgesia for treating dental pain in several studies [5,6]. Endodontic treatment with a lower prevalence of postoperative pain is usually the treatment of choice. There have been no controlled dental studies evaluating the additive effects of combining a non-steroidal anti-inflammatory drug with paracetamol. Breivik et al [6] & Menhinick et al [7] found that a combination of acetaminophen and ibuprofen was more effective than ibuprofen alone in managing postoperative pain. Aim of the present study, to evaluate the efficacy of the paracetamol when used alone and in combinations with three groups of drugs to control postoperative endodontic pain.

NCT ID: NCT01841541 Completed - Tuberculosis Clinical Trials

The Impact of Involving Informal Health Providers for Tuberculosis Control in Sudan

Triage-Plus
Start date: January 2009
Phase: N/A
Study type: Interventional

Training and engaging of unpaid informal providers (such as tea-sellers, women's groups, youth clubs, small traders and religious groups) from poorer localities in TB disease recognition, referral and community awareness raising will increase the access of TB patients to formal health facilities and decrease their delay in initiating TB treatment.